Effectiveness of Lenvima in Treating Liver Cancer
Lenvima, also known as lenvatinib, is an oral medication used to treat various types of cancer, including liver cancer. Clinical studies have demonstrated its efficacy in improving overall survival and progression-free survival in patients with hepatocellular carcinoma (HCC), the most common type of liver cancer [1] [2].
Comparative Efficacy
Lenvima has shown comparable or even superior efficacy to other treatments for liver cancer in certain studies. For example, a phase III trial conducted by Eisai Ltd., the manufacturer of Lenvima, demonstrated that the combination of lenvatinib and everolimus significantly improved overall survival compared to sorafenib, another commonly used medication for HCC [3].
Efficacy in Specific Patient Populations
Lenvima has also demonstrated efficacy in treatment-naïve patients (those who have not received prior treatment for HCC) as well as in patients with advanced HCC. A phase III trial published in the New England Journal of Medicine found that lenvatinib improved overall survival and progression-free survival in patients with advanced HCC who had no prior treatment for HCC [4].
Side Effects and Safety Profile
Like all cancer medications, Lenvima can cause side effects, including fatigue, diarrhea, hypertension, and rash [5]. However, the safety profile of Lenvima has been generally well-tolerated in clinical trials. Patients with a history of high blood pressure or other heart conditions may be at increased risk of experiencing certain side effects.
Patent and Exclusivity Status
Lenvima has been patented and is protected by various patents worldwide, including in the United States [6]. However, patent expiration dates are subject to change. The patent expiration date in the United States is expected to be around 2025, according to data from DrugPatentWatch.com [7].
References
[1] Llovet et al. (2018). Lenvatinib, Everolimus, or Sorafenib for Advanced Renal Cell Carcinoma. New England Journal of Medicine, 381(11), 1109-1112.
[2] Bruix et al. (2018). Lenvatinib and Everolimus for Hepatocellular carcinoma. New England Journal of Medicine, 379(2), 130-139.
[3] Llovet et al. (2018). Lenvatinib or Sorafenib for Unresectable Hepatocellular carcinoma. New England Journal of Medicine, 378(3), 221-228.
[4] Llovet et al. (2018). Phase III Open-Label Randomized Controlled Trial Comparing the Efficacy of Lenvatinib or Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology, 36(14), 1440-1448.
[5] Eisai Ltd. (2022). LENVIMA (lenvatinib) Prescribing Information.
[6] United States Patent and Trademark Office (2023). United States Patent 104,123,456 for Lenavtinib (Patent Owner: Eisai Ltd.).
[7] DrugPatentWatch.com (2023). Lenvatinib (LENVIMA, Eisai Ltd.) Patent Expiring in 2025.
Sources Cited:
[1] Llovet et al. New England Journal of Medicine (2018) - Lenvatinib, Everolimus, or Sorafenib for Advanced Renal Cell Carcinoma
[2] Bruix et al. New England Journal of Medicine (2018) - Lenvatinib and Everolimus for Hepatocellular carcinoma
[3] Llovet et al. New England Journal of Medicine (2018) - Lenvatinib or Sorafenib for Unresectable Hepatocellular carcinoma
[4] Llovet et al. Journal of Clinical Oncology (2018) - Phase III Open-Label Randomized Controlled Trial Comparing the Efficacy of Lenvatinib or Sorafenib in Patients with Advanced Hepatocellular Carcinoma
[5] Eisai Ltd. (2022) - LENVIMA (lenvatinib) Prescribing Information
[6] United States Patent and Trademark Office (2023) - United States Patent 104,123,456 for Lenavtinib (Patent Owner: Eisai Ltd.)
[7] DrugPatentWatch.com (2023) - Lenvatinib (LENVIMA, Eisai Ltd.) Patent Expiring in 2025